SMA (spinal muscular atrophy) is a hereditary condition that affects muscle movement control. It is caused by the loss of motor neurons, which are specialised nerve cells found in the spinal cord and brainstem. Motor neuron loss causes muscle weakness and atrophy in actions including sitting up, walking, crawling, and controlling head movement. In severe cases, the muscles involved in swallowing and breathing are also affected. The degree of muscle weakening, the pattern of features, and the age at which the muscle issues initially manifest are all characteristics of spinal muscular atrophy. There are three types: type 1, type 2, and type 3, all of which appear in childhood.
The global spinal muscular atrophy market size was valued at US$ 884 million in 2019 and is expected to witness a robust CAGR of 12.4% over the forecast period (2021–2027).
Request for a FREE Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/1920
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Increasing number of clinical trials and government funding for R&D is expected to bolster the spinal muscular atrophy market growth
Various government and private organisations are pouring large sums of money and resources into developing new and effective treatments for spinal muscular atrophy. The SMA Foundation, for example, invested over US$ 60 million in drug research initiatives and important drug discovery assets in 2015 with the goal of developing an effective SMA medication. Cytokinetics was awarded a grant from Cure SMA in 2013 to explore Tirasemtiv for SMA. The grant’s financial specifics were kept private. Tirasemtiv is a new skeletal muscle activator and a main medication candidate in Cytokinetics’ contractility programme. Clinical trials for amyotrophic lateral sclerosis patients have been conducted (ALS). ALS impairs motility in the same way that SMA does. Similar to SMA, ALS also affects motor neurons.
The National Institute of Neurological Disorders and Stroke (NINDS), which is part of the National Institutes of Health (NIH), conducts clinical, translational, and basic research on SMA, as well as funding research at major medical institutions in the United States through grants. The NeuroNext clinical trials network was formed by the authority in 2011 to support the quick development and implementation of trials for neurological illnesses that impact adults and/or children. The network’s goal is to create early-stage studies that will find biomarkers that may be used to evaluate the presence and severity of a disease, as well as test promising new medicines.
Request Here PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1920
Increasing incidence rate of spinal muscular atrophy worldwide is expected to augment the market growth
Because spinal muscular atrophy shows early in life, it is a common hereditary cause of infant death. One of the most common rare diseases is this one. According to the SMA Foundation’s 2015 figures, spinal muscular atrophy affects between 10,000 and 25,000 adults and children in the United States. SMA affects about 1 in 11,000 children, according to CureSMA, which was founded in March 2018. It has been found in people of every race, however, is most common in Caucasians, of whom 1 in 35 is a carrier. Spinal muscular atrophy carrier rates for other populations include Asians (1 in 53), African Americans (1 in 66), and Hispanics (1 in 117).
The high cost of therapy, on the other hand, may limit the market’s expansion during the projection period. Biogen’s Spinraza (nusinersen) drug for spinal muscular atrophy, for example, is estimated to cost US$ 125,000 per injection, with the first year costing US$ 750,000 and the second year costing US$ 375,000.Major players operating in the global spinal muscular atrophy market include Biogen, Cytokinetics, Inc., F. Hoffmann-La Roche, Novartis AG, Pfizer Inc., and Ionis Pharmaceuticals, Inc.
“Limited Period Offer”
Buy This Complete Business Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/1920
Main points in Spinal Muscular Atrophy Market Report Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Spinal Muscular Atrophy Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Spinal Muscular Atrophy Industry Impact
Chapter 2 Spinal Muscular Atrophy Competition by Types, Applications, and Top Regions and Countries
2.1 Spinal Muscular Atrophy (Volume and Value) by Type
2.3 Spinal Muscular Atrophy (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Spinal Muscular Atrophy Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Spinal Muscular Atrophy Market Analysis
Chapter 6 East Asia Spinal Muscular Atrophy Market Analysis
Chapter 7 Europe Spinal Muscular Atrophy Market Analysis
Chapter 8 South Asia Spinal Muscular Atrophy Market Analysis
Chapter 9 Southeast Asia Spinal Muscular Atrophy Market Analysis
Chapter 10 Middle East Spinal Muscular Atrophy Market Analysis
Chapter 11 Africa Spinal Muscular Atrophy Market Analysis
Chapter 12 Oceania Spinal Muscular Atrophy Market Analysis
Chapter 13 South America Spinal Muscular Atrophy Market Analysis
Chapter 14 Company Profiles and Key Figures in Spinal Muscular Atrophy Business
Chapter 15 Spinal Muscular Atrophy Market Forecast (2021-2027)
Chapter 16 Conclusions
Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1920
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027